These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10982197)

  • 41. Oxprenolol in schizophrenic patients with tardive dyskinesia: a double-blind placebo-controlled, crossover study.
    Karniol IG; Portela W
    Braz J Med Biol Res; 1982 Dec; 15(6):389-94. PubMed ID: 6135468
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholinergic medication for neuroleptic-induced tardive dyskinesia.
    Tammenmaa IA; McGrath JJ; Sailas E; Soares-Weiser K
    Cochrane Database Syst Rev; 2002; (3):CD000207. PubMed ID: 12137608
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
    Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
    J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Tardive dyskinesia in patients with schizophrenia treated with olanzapine - results from a 20-month, prospective, open study under naturalistic conditions].
    Szafrański T
    Psychiatr Pol; 2014; 48(6):1155-65. PubMed ID: 25717485
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    McGrath JJ; Soares KV
    Cochrane Database Syst Rev; 2000; (2):CD000459. PubMed ID: 10796546
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial.
    Emsley R; Niehaus DJ; Koen L; Oosthuizen PP; Turner HJ; Carey P; van Rensburg SJ; Maritz JS; Murck H
    Schizophr Res; 2006 May; 84(1):112-20. PubMed ID: 16632329
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
    Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Tardive dyskinesia: a review.
    Latimer PR
    Can J Psychiatry; 1995 Sep; 40(7 Suppl 2):S49-54. PubMed ID: 8564917
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Sulpiride in tardive dyskinesia.
    Casey DE; Gerlach J; Simmelsgaard H
    Psychopharmacology (Berl); 1979; 66(1):73-7. PubMed ID: 44375
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.
    Zhang XY; Zhou DF; Cao LY; Xu CQ; Chen DC; Wu GY
    J Clin Psychopharmacol; 2004 Feb; 24(1):83-6. PubMed ID: 14709952
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tardive dyskinesia rates with atypical antipsychotics in older adults.
    Jeste DV
    J Clin Psychiatry; 2004; 65 Suppl 9():21-4. PubMed ID: 15189108
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Calcium channel blockers for neuroleptic-induced tardive dyskinesia.
    Essali A; Deirawan H; Soares-Weiser K; Adams CE
    Cochrane Database Syst Rev; 2011 Nov; (11):CD000206. PubMed ID: 22071797
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of ceruletide on tardive dyskinesia: a double-blind placebo-controlled study.
    Matsunaga T; Ohyama S; Takehara S; Kabashima K; Moriyama S; Tsuzuki J; Ikeda H; Suematsu M; Akizuki K; Fujimoto K
    Prog Neuropsychopharmacol Biol Psychiatry; 1988; 12(4):533-9. PubMed ID: 3043555
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Benefits of trazodone and mianserin for patients with late-life chronic schizophrenia and tardive dyskinesia: an add-on, double-blind, placebo-controlled study.
    Hayashi T; Yokota N; Takahashi T; Tawara Y; Nishikawa T; Yano T; Furutani M; Fujikawa T; Horiguchi J; Yamawaki S
    Int Clin Psychopharmacol; 1997 Jul; 12(4):199-205. PubMed ID: 9347380
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Benzodiazepines for neuroleptic-induced tardive dyskinesia.
    Bhoopathi PS; Soares-Weiser K
    Cochrane Database Syst Rev; 2006 Jul; (3):CD000205. PubMed ID: 16855954
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Therapeutic measures in tardive dyskinesia].
    Tegeler J; Wöller W
    Fortschr Neurol Psychiatr; 1983 Jun; 51(6):203-26. PubMed ID: 6136457
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Tardive dyskinesia: clinical, biological, and pharmacological perspectives.
    Berger PA; Rexroth K
    Schizophr Bull; 1980; 6(1):102-16. PubMed ID: 6102788
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The treatment of tardive dyskinesia.
    Raja M
    Schweiz Arch Neurol Psychiatr (1985); 1996; 147(1):13-8. PubMed ID: 8685689
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Melatonin for the treatment of tardive dyskinesia.
    Nelson LA; McGuire JM; Hausafus SN
    Ann Pharmacother; 2003; 37(7-8):1128-31. PubMed ID: 12841828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.